[Skip to Content]
[Skip to Content Landing]
Other Articles
June 9, 1962


JAMA. 1962;180(10):833-834. doi:10.1001/jama.1962.03050230035014

At the Second Workshop on Lung Cancer Research sponsored by the American Cancer Society in 1959, it was suggested that a careful analysis be made of available data pertaining to results obtained with pneumonectomy and lobectomy in the treatment of lung cancer. In response to this suggestion, Dr. Alton Ochsner of New Orleans and Dr. Richard H. Overholt of Boston agreed to permit the Biometry Branch of the National Cancer Institute, U. S. Public Health Service to analyze the survival experience of their surgically treated patients. Dr. Ochsner has been a leading exponent of pneumonectomy in the treatment of lung cancer. Dr. Overholt has in recent years shifted to the use of lobectomy as the treatment of choice.

The results of this independent appraisal are now available.1 The data at hand indicate that among patients with localized disease, survival was similar whether lobectomy or pneumonectomy was performed. Among patients with